迪迪明通过增强高脂肪饮食引起的葡萄糖耐受性受损的线粒体功能来保护胰腺β细胞
Jingwen Yang1, Ying Zou1, Xiaoyu Lv1
1Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, 250012, Jinan, Shandong, China.
Diabetology & metabolic syndrome
|January 4, 2024
概括
滴滴胺是一种类黄类物质,可以保护胰腺β细胞免受高脂肪饮食损害. 它通过增强线粒体功能和胰岛素分泌来改善葡萄糖耐受性,为2型糖尿病提供治疗潜力.
科学领域:
- 代谢性疾病研究研究.
- 营养生物化学 营养生物化学
- 细胞生物学 细胞生物学
背景情况:
- 长时间高血自由脂肪酸 (FFA) 会导致葡萄糖耐受性受损 (IGT),可能会发展为2型糖尿病 (T2D).
- 高脂肪饮食 (HFD) 诱导慢性炎症和氧化应激,损害胰腺β细胞 (PBC) 功能.
- 丁胺是一种黄类化合物,具有抗炎作用,但其在HFD诱导的IGT中的作用尚不清楚.
研究的目的:
- 研究Didymin对胰腺β细胞 (PBCs) 的保护作用,在高脂肪饮食引起的葡萄糖耐受性损失 (IGT) 中.
主要方法:
- 利用HFD诱导的IGT小鼠和INS-1细胞来研究Didymin的作用和机制.
- 通过葡萄糖和胰岛素耐受性测试评估血清葡萄糖和胰岛素水平.
- 采用RNA-seq来识别受迪迪明和罗影响的途径,以确认线粒体增强.
主要成果:
- 迪迪明改善了IGT小鼠的食后血糖和胰岛素水平.
- 增强线粒体生物发生和功能,调节胰岛素分泌,减少炎症和亡.
- 这些好处被Rotenone扭转,证实了Didymin的机制涉及线粒体增强.
结论:
- 迪迪明证明了高脂肪饮食诱导的葡萄糖耐受性损失 (IGT) 的治疗潜力.
- 迪迪明通过改善线粒体功能来改善胰腺β细胞 (PBC) 功能障碍.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325


